Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

The rising incidence of antimicrobial resistance (AMR) makes it imperative to understand the
underlying mechanisms. Mycobacterium tuberculosis (Mtb) is the single leading cause of …

Mycobacterium tuberculosis (Mtb) encounters stresses during the pathogenesis and
treatment of tuberculosis (TB) that can suppress replication of the bacteria and render them …

Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (…

It is urgent to introduce new drugs for tuberculosis to shorten the prolonged course of treatment
and control drug-resistant Mycobacterium tuberculosis (Mtb). One strategy toward this …

Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

The search for drugs that can kill replicating and nonreplicating Mycobacterium tuberculosis
faces practical bottlenecks. Measurement of CFU and discrimination of bacteriostatic from …

Identification of compounds that target metabolically diverse subpopulations of Mycobacterium
tuberculosis (Mtb) may contribute to shortening the course of treatment for tuberculosis. …

Tuberculosis remains one of the deadliest infectious diseases, killing 1.4 million people
annually and showing a rapid increase in cases resistant to multiple drugs. New antibiotics …

BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate
the inflammatory response in Covid-19. METHODS We performed an adaptive, phase 2/3, …